Estrogen receptor b (ERb) is expressed in immune cells and studies have suggested an antiproliferative function of ERb. We detected ERb expression in murine T-and human B-cell lymphoma cell lines and analyzed the effects of estradiol and selective ERb agonists on lymphoma growth in culture and in vivo. Treating the cells with estradiol had minor effects on cell growth, whereas the selective ERb agonists diarylpropionitrile (DPN) and KB9520 showed a strong antiproliferative effect. When grafting mice with murine T-cell lymphoma cells, male mice developed larger tumors compared with female mice, a difference that was abolished following ovariectomy, showing estrogen-dependent growth in vivo. To investigate whether lymphoma growth may be inhibited in vivo by ERb agonist treatment, mice grafted with murine lymphoma cells were treated with DPN or KB9520. Both ERb-selective agonists strongly inhibited lymphoma growth. The reduced tumor size seen following either DPN or KB9520 treatment was due to reduced proliferation and increased apoptosis. Our results show an ERb ligand-dependent antiproliferative effect of lymphoma cells expressing endogenous ERb and that lymphoma cell growth in vivo can efficiently be inhibited by ERb agonists. This suggests that ERb agonists may be useful in the treatment of lymphomas.
Introduction
Estrogens are important signaling molecules that regulate various physiological processes such as cell growth, reproduction, development and differentiation. They also have a role in several pathological processes of hormone-dependent diseases, including cancers. 1 Cellular signaling by estrogens is mediated via the estrogen receptors a and b (ERa and ERb). 2 In human beings, ERa is mainly expressed in reproductive tissues (uterus, ovary), breast, kidney, bone, white adipose tissue and liver, whereas the highest levels of ERb expression is found in the ovary, central nervous system, cardiovascular system, lung, male reproductive organs, prostate, colon, kidney and the immune system. 3, 4 With regard to the immune system, previous studies have shown that ERb is the dominant ER expressed in mature leukocytes from peripheral blood, tonsils or spleen of healthy individuals. 5 Furthermore, in several human lymphoma cell lines, including Hodgkin's lymphoma, Burkitt's lymphoma and multiple myeloma, ERb is abundantly expressed while ERa is not detectable. 5 Although the main physiologically active estrogen, 17b-estradiol (E 2 ), binds and activates both ERa and ERb, the two ER's exert different biological responses. 2 This means that the ratio of ERa/ERb in any given cell or tissue will determine the response to estrogen. Several studies have suggested that ERa and ERb elicit opposite effects on cell proliferation. Although estrogens via ERa stimulates proliferation in the breast, uterus and developing prostate, [6] [7] [8] thereby increasing the risk of tumor development and progression, estrogens via ERb inhibit proliferation and promotes differentiation of the prostate, mammary gland, colon, lung and stem cells of the bone marrow. [9] [10] [11] [12] [13] An antiproliferative effect of ERb is also suggested from experiments in ERb knockout mice, which display a myeloproliferative disease resembling human chronic myeloid leukemia with lymphoid blast crisis and prostate hyperplasia, suggesting that ERb may act as a tumor suppressor. 9, 13 Furthermore, transfection of ER-negative cancer cell lines with ERb also results in reduced proliferation. 14, 15 Cancers of the reproductive tissues, prostate and colon are well-known cancers to involve estrogen signaling. Also, lymphoid malignancies may show estrogen dependency as several epidemiological studies of cancers of lymphoid origin show a gender difference with regard to both incidence and prognosis. For example, the incidence of chronic lymphocytic leukemia in men is almost two times higher than that in women. Moreover, female patients have better prognosis independently of chronic lymphocytic leukemia stage and age. 16 Higher incidence of B-precursor acute lymphocytic leukemia was also shown in male patients. 17 In addition, several lymphomas are also characterized by increased male to female ratio. For T-cell peripheral lymphomas, a male/female incidence rate ratio of 1.8 has been reported. 18 Furthermore, women have a lower incidence of non-Hodgkin's lymphoma than men, 19 and the male sex has been suggested to be a risk factor for Burkitt's lymphoma. 20 Considering ERb being the main ER expressed in lymphoid tissues and its generally antiproliferative effect, we hypothesized that the reduced incidence/better prognosis of lymphoid cancers in women may be related to more pronounced ERb-mediated actions of estrogens. Moreover, targeting ERb in lymphoid tumors with estrogens may therefore be useful in the treatment of lymphomas. However, as treatment with estrogens with no selectivity for ERb vs ERa has been associated with severe side effects, for example, increased breast and uterus cancer risk, 21, 22 highly selective ERb agonists are under development for clinical use. 23 The experimentally most commonly used selective ERb agonist, diarylpropionitrile (DPN), displays a 70-fold binding preference for ERb over ERa. 24 In this report, we have used DPN and a newly developed highly selective ERb agonist, KB9520, which displays a 700-fold selectivity for ERb over ERa. Using DPN and this highly selective ERb agonist, we showed that targeting ERb in a murine T-cell lymphoma in culture and in vivo, as well as in human Burkitt's lymphoma-derived cell lines, results in an antiproliferative effect. Treatment of mice grafted with the murine T-cell lymphoma with selective ERb agonist also enhances apoptosis. These results suggest that selective ERb agonists inhibit lymphoma growth and may therefore be useful in the treatment of these diseases.
Materials and methods

Materials
Murine mouse T lymphoma cell line EG7, 25 
Cell lines and treatments in culture
Murine mouse T lymphoma cell line EG7, 25 murine hepatoma Hepa1c1c7, human B-cell Burkitt's lymphoma cell lines Raji and Ramos and HEK293 cells were maintained in RPMI 1640 (EG7, Raji, Ramos) or Dulbecco's modified Eagle's medium (Hepa1c1c7, HEK293, MCF-7) medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 IU of penicillin per ml and 100 mg/ml of streptomycin at 37 1C in 5% CO 2 . The cells were treated with 10 nM DPN, 100 nM KB9520, 10 nM E 2 , 10 nM PPT or vehicle (DMSO) for up to 96 h in phenol red-free culture medium supplemented with 10% charcoal-purified fetal bovine serum and 1% L-glutamine at 37 1C in 5% CO 2 . The final DMSO concentration was o0.001% in all cell culture experiment. Cell proliferation was evaluated using a Bü rker cell counter. Cell viability was determined by Trypan blue exclusion.
Transfections, treatments and reporter gene assay HEK293 cells were transfected with the ERE 2 tk-luc reporter gene 27 alone or together with CMV-FLAG-ERa or CMV-FLAG-ERb expression vectors using Lipofectamine (Invitrogen, Carlsbad, CA, USA) or Mirus (Mirus Bio LCC, Madison, WI, USA) transfection reagents. After 24 h, the transfected cells were treated with either 10 nM E 2 , 100 nM of selective ERb agonist KB9520, 10 nM of the ERa agonist PPT or vehicle (DMSO) alone in phenol red-free RPMI 1640 medium supplemented with 10% charcoal-purified estrogen-free fetal bovine serum and 1% L-glutamine at 37 1C in 5% CO 2 . Alternatively, HEK293 cells were co-transfected with the ERE 2 tk-luc reporter gene together with either ERa or ERb expression vector and treated with increasing concentrations of KB9520. After 24 h of treatment, the supernatants were removed and the cells were lysed with lysis buffer (25 mM Tris, 2 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM dithiothreitol). The cell lysates were incubated for 2 h at À20 1C and for 45 min at 4 1C using a shaker. Luciferase activity was analyzed by a Tecan Luminometer.
Mice C57BL/6J mice (8-10 weeks of age) were purchased from Taconic (Lille Skensved, Denmark). Mice were housed 12 h light/12 h darkness cycles at a temperature of 21-22 1C and a relative humidity of 50-62%, with free access to fresh water and soy-free food pellets (Lactamin AB, Stockholm, Sweden), at the infection-free animal facility of Karolinska University Hospital (Huddinge, Sweden). Mice were kept on soy-free diet starting from 2 weeks before the experiments. Animal care was in accordance with the guidelines of Karolinska Institutet and all animal experiments were performed in accordance with ethical committee approval.
Ovariectomy, tumor grafting, in vivo treatments and tumor growth measurements Both ovariectomy and sham operations were performed under intraperitoneal anesthesia with 100 mg Midazolam (Roche Diagnostics, Indianapolis, IN, USA), 1.5 mg Domitor (Orion Corporation, Espoo, Finland) and 0.05 mg Fentanyl (JanssenCilag, Sollentuna, Sweden) in 100 ml of physiological NaCl solution per mouse. A 5 mm incision was made through the skin of the lower part of the back of the mouse. Peritoneum was opened and ovaries were removed with sterile scissors. The skin incision was closed with wound clips. The sham-operated mice were treated in the same way, except that the ovaries were not removed. The mice were allowed to recover for 10 days before the start of the experiments. For lymphoma grafting, mice were subcutaneously injected in the right flank with 2.5 Â 10 5 EG7 lymphoma cells in 100 ml of sterile phosphate-buffered saline (PBS). Starting from the day when tumor cells were injected, animals were treated subcutaneously in the left flank with E 2 (2.3 mmol/kg body weight), DPN (12.5 mmol/kg body weight), PPT (13 mmol/kg body weight), ICI 182.780 (1.65 mmol/kg body weight), KB9520 (28 mmol/kg body weight) or a combination of ICI 182.780 and KB9520 (1.65 and 28 mmol/kg body weight, respectively) in 5% DMSO/40% polyethylene glycol 400/55% water or with vehicle alone in a total volume of 100 ml per mouse per day for 11-14 days. Tumor growth was measured daily and tumor volume (TW) was calculated as TW (mm 3 ) ¼ 0.5 Â length (mm) Â width (mm 2 ) using a caliper. The animals were killed at the latest at day 14 after grafting of lymphoma cells (TW o500 mm 3 ) according to the ethical regulations for the research project. No signs of pain or physical discomfort among the mice were observed.
Immunofluorescence/immunocytochemistry and TUNEL assay
In total, 10 5 cells were attached to glass slides by cytospine cytocentrifuge (Thermo Fisher Scientific, Waltham, MA, USA) at 500 r.p.m. for 15 min. Before staining, cells were fixed with 4% paraformaldehyde (Merck, Whitehouse Station, NJ, USA) for 15 min at 4 1C and permeabilized with 0.5% Triton X-100 for 10 min at room temperature. The slides were blocked for 1 h at 4 1C with 1% bovine serum albumin (Sigma-Aldrich) in PBS. After blocking, the slides were incubated overnight at 4 1C with primary antibodies against ERa (rabbit MC-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:100 or ERb (chicken ERb503 antibody) 28 diluted 1:200 in PBS containing 0.1% bovine serum albumin, followed by incubation with the corresponding secondary Cy3-conjugated goat anti-rabbit or goat anti-chicken antibodies for 1 h at room temperature. The anti-ERb503 antibody does not stain tissues from ERb-null mice, whereas staining is seen in the corresponding tissues of wild-type mice. [29] [30] [31] Nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (Sigma-Aldrich). Images were made using a Zeiss Axioplan2 immunofluorescence microscope.
Tumor tissues were fixed with freshly prepared 4% paraformaldehyde in PBS and washed with 50% ethanol before dehydration and paraffin embedding. Paraffin-embedded blocks were cut to 5 mm and mounted on polylysine-charged glass slides. Antigen retrieval was performed following deparaffinization by microwaving sections in 0.01 M citrate buffer, pH 6.0. The sections were permeabilized with 0.1% NP40 in PBS for 10 min at room temperature. For Ki67 staining, tissue sections were incubated for 1 h at 4 1C with 1% bovine serum albumin and 10% of normal mouse serum in PBS. The slides were incubated overnight at 4 1C with primary antibodies against Ki67 (Dako, Carpinteria, CA, USA), followed by incubation with Alexa Fluor 568-labeled secondary antibody (Invitrogen) for 1 h at room temperature.
The TdT-mediated dUTP nick-end labeling (TUNEL) assay was performed according to the manufacturer's protocol (Roche Diagnostics). After rinsing slides twice with PBS, 50 ml of TUNEL reaction mixture was added to each tumor section. The slides were incubated in a humidified chamber for 60 min at 37 1C in the dark and rinsed three times with PBS. For immunofluorescence, slides were mounted in fluorescence mounting medium (Dako). The sections were examined under Zeiss Axioplan 2 fluorescence microscope, with filters suitable for selectively detecting the fluorescence of Alexa Fluor 568 (red), tetramethylrhodamine (red), fluorescein isothiocyanate (green) and 4 0 ,6-diamidino-2-phenylindole (blue). Quantification of the Ki67 and TUNEL assays were performed by counting the number of stained cells from four randomly chosen fields (at 200-fold magnification) from each tumor.
Results
Murine T-cell lymphoma cells EG7 and human B-cell Burkitt's lymphoma cells Raji and Ramos express ERb, but not ERa protein
Previous studies have shown that ERb is the main ER expressed in cells of lymphoid origin. To characterize ER expression in murine and human lymphomas, the expression of ERb and ERa in the murine T-cell lymphoma cell line EG7 and the human B-cell Burkitt's lymphoma cell lines Raji and Ramos was analyzed. Immunofluorescence showed significant nuclear expression of ERb in murine EG7 cells (Figure 1a) . Almost all EG7 cells expressed ERb, except for a small population of EG7 cells that were negative. Staining for ERa was negative in all EG7 lymphoma cells (Figure 1b) . To confirm the ERb specificity of the 503 antibody used for immunofluorescence, murine hepatoma cells Hepa1c1c7 were stained for ERb and showed to be negative (Figure 1c) , unless the cells were transfected with a murine ERb-expressing vector, confirming the ERb specificity of the 503 antibody used (Figure 1d ). Hepa1c1c7 cells were positive for ERa expression (Figure 1e ). Positive ERb staining was also seen in most human Raji and Ramos Burkitt's lymphoma cells (Figures 1f and g, respectively) . Figure S1 ).
Estradiol and selective ERb agonists inhibit growth of murine and human lymphoma cells in culture
ERb has been suggested to have an antiproliferative effect as opposed to ERa. 32 To analyze whether selective activation of ERb protein levels were detected in both human Raji (f) and Ramos (g) lymphoma cells using the anti-ERb 503 antibody.
Estrogen
ERb would affect growth of lymphoma cells, we used the selective ERb agonists DPN and KB9520. DPN has previously been shown to have a 70-fold selectivity for ERb over ERa. 24 The selectivity of KB9520 was determined by transfecting ER-negative HEK293 cells with an ER-responsive luciferase reporter gene alone or together with ERa-or ERb-expressing vectors, whereafter cells were treated with E 2 (which activates both ERa and ERb), the ERa-selective agonist PPT or the ERb agonist KB9520. In the absence of co-transfected ERs, no stimulation of reporter gene expression was seen with any of the ER ligands (data not shown). Treatment of ERa-transfected HEK293 cells with either E 2 or PPT resulted in a strong stimulation of reporter gene expression, whereas negligible transcriptional activation of the reporter gene was observed for KB9520 (Supplementary Figure 2A) . As expected, treatment of ERb-transfected HEK293 cells with E 2 , but not PPT, resulted in a robust stimulation of reporter gene expression. However, in contrast to the inability of KB9520 to activate ERa, KB9520 efficiently activated ERb (Supplementary Figure 2B) . These results show that KB9520 is a selective activator of ERb. To more quantitatively determine the selectivity of KB9520 for ERb over ERa, HEK293 cells, genetically engineered to stably express human ERa and ERb, respectively, were used as described previously. 33 The dose-response curves showed an EC 50 value of 6.7 nM for KB9520 in the HEK293-ERb cells and B4.9 mM for ERa in the HEK293-ERa cells, that is, KB9520 is a highly ERbselective agonist with approximately 700-fold selectivity for ERb over ERa (Supplementary Figure 2C) .
To test the antiproliferative effect of activated ERb, EG7, Raji and Ramos cells were treated with either E 2 , selective ERa agonist PPT or selective ERb agonists KB9520 or DPN in culture. The results showed a statistically significant inhibition of growth of EG7, Raji and Ramos cells by both DPN and KB9520 (Figures  2a-c) . The effect of KB9520 increased from mild inhibition at the 48 h time point to strong inhibition at 72 and 96 h as compared with vehicle-treated cells (upper panel). Similar results on proliferation were seen when cells were treated with the ERb-selective agonist DPN (lower panel). The inhibitory effect of E 2 on EG7, Ramos and Raji cells was much lower than the effect of the selective ERb agonists and only statistically significant at 72 h, but not at 96 h (Figures 2a-c, upper panel) . PPT did not significantly affect the growth of either murine EG7, human Ramos or Raji cells, in line with a lack of detectable or very low expression of ERa in these cells (Figures 2a-c, lower  panel) . Neither DPN nor KB9520 affected cell growth of the ERa-positive ERb-negative Hep1c1c7 cells (data not shown).
Allografting of EG7 lymphoma cells to mice results in larger tumors in male as compared with female mice
The ERb-expressing EG7 lymphoid cells were subcutaneously grafted to male and female syngenic C57BL/6J mice to explore the gender difference in EG7 tumor cell growth. Following subcutaneous injection of the cells into mice, male mice developed larger tumors than intact female mice. Moreover, in intact female mice tumor development was delayed by 2 days (Figure 3 ). However, in contrast to intact female mice, EG7 growth rate and tumor development was the same in ovariectomized mice as in male mice (Figure 3 ). These data suggest that endogenous estrogens can inhibit EG7 lymphoma growth in vivo via ERb, and, furthermore, that the higher circulating E 2 levels in intact female mice as compared with male mice explains, at least in part, the sex difference in EG7 lymphoma growth and tumor development. Similar to EG7 cells in culture, ERb, but no ERa, was found to be expressed also in growing tumors in vivo as analyzed by immunofluorescence (data not shown).
Treatment with selective ERb agonists DPN or KB9520 suppresses lymphoma growth in vivo
To evaluate if a selective ERb agonist would suppress lymphoma growth in vivo, EG7 cells were grafted subcutaneously to male C57BL/6J mice, followed by daily subcutaneous injections of the ERb-selective agonists DPN or KB9520 and the ERa-selective agonist PPT. Treatment with DPN or KB9520 significantly suppressed lymphoma growth in male mice in comparison to vehicle-treated mice (Figures 4a and b, respectively) Estrogen receptor b agonists suppress lymphoma growth K Yakimchuk et al no effect on lymphoma growth (Figure 4a ). KB9520 efficiently inhibited EG7 lymphoma growth also in female ovariectomized mice, whereas only a weak suppression of tumor growth was observed by E 2 treatment (Supplementary Figure 3A) . KB9520 did not affect uterus growth (an ERa-mediated effect) in contrast to E 2 treatment, which resulted in strong uterus growth and weight, showing ERb-selective activity of KB9520 also in vivo (Supplementary Figures 3B and C) .
To show that the inhibition of lymphoma growth by KB9520 is an ER-mediated effect and not an off-target effect, tumor cell-grafted male mice were also treated with the anti-estrogen ICI 182.780 in combination with KB9520. Co-treatment with ICI 182.780 completely blocked the ability of KB9520 to significantly inhibit lymphoma growth, clearly showing an ER-mediated effect of KB9520 (Figure 4b ).
In vivo treatment with DPN or KB9520 represses proliferation and increases apoptosis in the murine lymphoid tumor
To evaluate the cause for the decreased tumor mass following the treatment by DPN or KB9520, cell proliferation and apoptosis was examined in tumor sections by Ki67 staining and TUNEL assay, respectively. The expression of Ki67 was significantly lower in tumors from mice treated with either DPN or KB9520 than in tumors from the vehicle-treated group (Figure 5a ). In contrast, apoptosis was significantly increased following both DPN and KB9520 treatment (Figure 5b ). This showed that the decreased tumor mass following treatment of the EG7 lymphoma tumor with either DPN or KB9520 was due to both inhibition of proliferation and increased apoptosis.
Discussion
In this report, we have shown that targeting ERb in lymphoma cells with highly selective ERb agonists resulted in both an antiproliferative effect and an increase in apoptosis of a murine lymphoma cell line (EG7) grafted to syngenic mice. This effect in turn resulted in a significantly reduced tumor mass. The antiproliferative effect extends also to at least two humanderived lymphoma cell lines, Raji and Ramos, in culture. The EG7 murine tumor cell line used originates from a mouse thymoma, whereas human Raji and Ramos cells are Burkitt's lymphoma cells of B-cell origin. This suggests that lymphoma cells of both T-and B-cell origin respond with an antiproliferative effect to ERb agonists. The effect seems also to be Figure 4 DPN or KB9520, but not PPT, inhibited EG7 lymphoma growth in vivo. Male C57BL/6J mice were subcutaneously grafted with EG7 lymphoma cells and treated daily for 14 days with either the ERb-selective agonist DPN (12.5 mmol/kg per day) (m), KB9520 (28 mmol/kg per day) (.), the ERa-selective agonist PPT (13 mmol/kg per day) (E), the ER antagonist ICI182.780 (1.65 mmol/kg per day) (J), a combination of KB9520 þ ICI182.780 (using the above amounts) (&) or vehicle (K). The tumors were allowed to grow for 14 days and tumor size was monitored daily. Each group consisted of six mice. Vehicle vs DPN or KB9520; *Po0.05. No significant difference was seen for the other treatments vs control (vehicle). Estrogen receptor b agonists suppress lymphoma growth K Yakimchuk et al independent of whether the lymphoma cells are Epstein-Barr virus positive (Raji) 34 or negative (Ramos). 35 To note is that the antiproliferative effect was observed for two selective ERb agonists belonging to structurally separate classes, supporting that the effects observed were ERb specific. This was further strengthened by the ability of an ER antagonist to block the antiproliferative effect of KB9520. That endogenous estrogens can influence EG7 tumor growth in vivo was supported by the increased tumor growth rate observed in ovariectomized mice as compared with intact female mice. This most likely explains the difference in tumor proliferation in male vs female mice as tumor growth rate was similar in ovariectomized mice as in male mice. Antiproliferative effects of endogenous estrogens via ERb in cells of lymphoid origin may also explain the gender difference clinically observed for the incidence and prognosis of some leukemias and lymphomas (for references see Introduction). However, gender differences may also operate through alternative mechanisms as ER expression is not found in all leukemias. 36 Considering E 2 being an efficient agonist for both ERa and ERb, E 2 had a surprisingly small antiproliferative effect on EG7 murine lymphoma growth in vivo and in vitro compared with DPN or KB9520. This could possibly be explained by the presence of small, but by immunocytochemistry undetectable, levels of ERa in these cells that in the presence of E 2 counteracts ERb activity. Alternatively, the ERb bound to E 2 vs a selective ERb agonist may result in a difference in cofactor recruitment leading to different efficacies to inhibit cell proliferation. Importantly, in vivo administration of KB9520, which resulted in a significant reduction in tumor mass, did not affect uterus size or weight showing that the in vitro selectivity translated to in vivo.
So far, the majority of studies investigating the effect of ERb on proliferation have been performed using cell lines engineered to express ERb. Previous studies showed that introduction of ERb into breast cancer cells and colon cancer cells inhibits cancer cell proliferation and tumor formation in mouse xenograft models. 14, 15, 37 However, in most of these experiments a ligandindependent ERb effect was observed. This may reflect the fact that a number of ERb target genes may be regulated by unliganded ERb. 38 Although previous studies have shown that cells of lymphoid origin express ERb at the protein level, very few have addressed the use of ERb-selective agonists on leukemias/lymphomas. A soy-derived isoflavone, genistein, with some selectivity for ERb, was recently shown to inhibit the growth of canine lymphoid cell lines. 39 Interestingly, similar to human beings, female dogs were shown to have a significantly lower risk of developing canine lymphomas than male dogs. 40 Although a wide spectrum of ERb-selective agonists is under development by pharmaceutical companies, 23 they have not been tested as potential therapeutic reagents for hematological tumors. To our knowledge, the data in this report are the first to show an antiproliferative and pro-apoptotic effect of endogenously ERb-expressing lymphoma cells in culture and in vivo by highly selective ERb agonists.
Several previous studies have shown that normal lymphoid cells preferentially express ERb. 5 In this study, we show that lymphoma cells EG7, Raji and Ramos also express ERb. This is interesting since studies of cell lines derived from several solid cancers, such as colon cancer and breast cancer, have shown that the expression of ERb is strongly reduced. 41 This has been claimed to be due to ERb promoter methylation occurring during the malignant transformation. [42] [43] [44] In the case of breast, colon and prostate cancer, as well as brain astrocytic tumors, ERb expression has been correlated to a higher tumor differentiation grade, in line with its antiproliferative and differentiating effects. [45] [46] [47] [48] It is of interest that malignant lymphoid cells, as described for the cell lines used in this report, retain ERb expression. This may suggest that malignant transformation of cells of lymphoid origin is not generally associated with the loss of ERb expression and therefore remain as useful targets for therapy by ERb agonists. In line with this, both peripheral blood mononuclear cells and chronic lymphocytic leukemia do express ERb (K Yakimchuk et al., manuscript submitted). In addition, further experiments will be important to show whether ERb agonists may not only exert an antiproliferative and pro-apoptotic effect, but also induce differentiation of lymphoid cells. 46 Our results showed that ERb activation by the ERb-selective agonists DPN and KB9520 resulted in both antiproliferative and pro-apoptotic effects in EG7 lymphoid tumors. Also, previous studies have shown pro-apoptotic effects by ERb signaling. U937 monocytes expressing mainly ERb were shown to be sensitive to estrogen-induced apoptosis. 49 Furthermore, ERb transmits signals for the pro-apoptotic event of Bax translocation in human macrophages. 50 Recent studies have shown that ERb agonist also induces apoptosis in prostatic epithelial cells of estrogen-deficient aromatase knockout mice. 51 Thus, ERbinduced apoptosis may be a more general event.
Estradiol affects cells of both the innate and adaptive immune system and female sex hormones have an important function in the pathogenesis of chronic inflammatory diseases. 52, 53 ERb is an effective repressor of nuclear factor-kB transcriptional activity suggesting an anti-inflammatory function of ERb. 54 Considering a stimulatory function of nuclear factor-kB on inflammatory gene expression and the connection between inflammation and cancer promotion, ERb agonist may have a potential function in inhibiting tumor growth also through this signaling pathway. In addition, the fact that ERb is expressed in lymphocytes may also have implications for tumor surveillance as lymphocyte infiltration occurs frequently in cancers. Thus, in addition to direct antiproliferative or pro-apoptotic effects on tumor cells, selective ERb agonists may be effective to potentiate immune antitumor activity through indirect mechanisms. Further studies are required to evaluate the effects of selective ERb agonists on differentiation, cytokine production and tumor surveillance by immune cells.
In summary, we have shown that lymphoma proliferation can be effectively suppressed by the activation of ERb by selective ERb agonists in culture and in vivo. We therefore suggest that selective ERb agonists might be useful for therapy of ERb-expressing lymphomas. Our results may also give an explanation to the clinically observed lower incidence and better prognosis of lymphomas in women than in men. Studies on primary cells obtained from clinical material may further prove this hypothesis.
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